drugset / Trial / NCT05625724

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

NCT05625724 ↗

Phase 3 Recruiting 1164 enrolled University Hospital, Toulouse
RandomizedParallel-groupDouble-blindPrevention

Summary

This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.

Timeline

Start
2023-08-02
Primary completion
2028-08
Completion
2029-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 150 mg —

Indications